Hung Pham Van, Nguyen Thai Duy, Ha Luu Thi, Toi Phung Lam, Tram Tran Hong
National Institute for Control of Vaccine and Biologicals, Hanoi 100000, Vietnam.
Institute of Reproductive and Child Health/Ministry of Health Key Laboratory of Reproductive Health and Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100191, China.
Vaccines (Basel). 2023 Jun 13;11(6):1097. doi: 10.3390/vaccines11061097.
Mixing vaccines was proposed as a solution to tackle supply chain interruptions during the crisis of the COVID-19 pandemic. This study aimed to investigate the safety of mixing COVID-19 vaccines for a booster dose in Hanoi, Vietnam.
A cross-sectional study was conducted via a telephone-based interview to identify the adverse events following COVID-19 vaccination among 719 participants in Hanoi, Vietnam.
In total, 45.76% of participants experienced at least one adverse event following two doses of the COVID-19 vaccine. Most of the adverse events were local effects with mild symptoms such as fever, headache, muscle pain, and/or pain at the site. In general, matching two doses in the same vaccines was not associated with the adverse events as compared to mixing vaccines (OR = 1.43, 96%CI: 0.93-2.2), except matching two doses of Pfizer (OR = 2.25, 95%CI: 1.33-3.82).
The findings of this study suggest the overall safety of mixed vaccination. In light of the vaccine shortage, mixing vaccinations for COVID-19 prevention is a good solution. Further studies with larger cohorts and investigating immunity following mixing vaccines are needed to elucidate the mechanism.
在新冠疫情危机期间，提出混合接种疫苗作为解决供应链中断问题的一种方案。本研究旨在调查在越南河内混合接种新冠疫苗作为加强针的安全性。
通过电话访谈进行横断面研究，以确定越南河内719名参与者接种新冠疫苗后的不良事件。
总体而言，45.76%的参与者在接种两剂新冠疫苗后经历了至少一种不良事件。大多数不良事件为局部反应，症状较轻，如发热、头痛、肌肉疼痛和/或接种部位疼痛。一般来说，与混合接种疫苗相比，同一疫苗接种两剂与不良事件无关（比值比=1.43，96%置信区间：0.93-2.2），但两剂均为辉瑞疫苗的情况除外（比值比=2.25，95%置信区间：1.33-3.82）。
本研究结果表明混合接种疫苗总体安全。鉴于疫苗短缺，混合接种疫苗以预防新冠是一个好的解决方案。需要开展更大样本量的进一步研究，并调查混合接种疫苗后的免疫情况，以阐明其机制。
